arrow
U

Ur Metser

university health network
H指数:48
被引数:8,493

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors and prevalence of lateral supraclavicular lymph node metastases on [18F]FDG PET/CT in patients with locally advanced, or multifocal invasive ductal carcinoma of breast: potential impact on adjuvant radiotherapy targets

局部晚期或多灶性浸润性导管癌患者腋上窝淋巴结转移的预测因素和[18F]FDG PET/CT上的患病率:对辅助放疗靶区选择的潜在影响

2026-09-090
OA
Prognostic value of [18F]FAZA PET/MR imaging pre and post revascularization in chronic limb-threatening ischemia: a prospective pilot study on tissue microcirculation

[18F]FAZA PET/MR成像在慢性肢体威胁性缺血患者再血管化前后的预后价值:一项关于组织微循环的前瞻性试点研究

2025-08-150
PRE
External Validation of a CT-Based Radiogenomics Model for the Detection of EGFR Mutation in NSCLC and the Impact of Prevalence in Model Building by Using Synthetic Minority Over Sampling (SMOTE): Lessons Learned

基于CT的放射基因组学模型在NSCLC中检测EGFR突变的体外验证,以及使用合成少数类过采样技术(SMOTE)进行模型构建时患病率的影响:经验总结

2025-05-150
OAAI
Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study

游离前列腺特异性抗原与总前列腺特异性抗原比值及18F-DCFPyL前列腺特异性膜抗原 PET/CT 检查结果在根治性前列腺切除术后的生化复发患者中的关联性:一项前瞻性单中心研究

2024-09-260
PRE
Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)

雄激素受体途径抑制剂 (ARPI) (SPLASH) 进展后,177Lu-PNT2002在PSMA阳性mCRPC中的疗效

2024-09-019
PRE